SNPMiner Trials by Shray Alag


SNPMiner SNPMiner Trials (Home Page)


Report for Mutation G212S

Developed by Shray Alag, 2020.
SNP Clinical Trial Gene

There is one clinical trial.

Clinical Trials


1 Biomarkers for Post-Transplant Lymphoproliferative Disorders in Children (CTOTC-06)

Solid organ transplantation is an important therapeutic option for children with a variety of end stage diseases. However, the same immunosuppressive medications that are required to prevent the child's immune system from attacking and rejecting the transplanted organ can predispose these individuals to developing a very serious cancer that is linked to Epstein-Barr virus (EBV).

NCT02182986 Heart Transplant Small Intestine Transplant Kidney Transplant Liver Transplant EBV-Related PTLD PTLDs Procedure: transplant Drug: Immunosuppressive Drugs
MeSH: Lymphoproliferative Disorders
HPO: Lymphoproliferative disorder

Specified gain-of-function mutations in EBV LMP-1 (e.g., corresponding to EBV LMP-1 variants G212S or S366T) detected by polymerase chain reaction (PCR) method. --- G212S ---

Primary Outcomes

Description: The development of EBV positive PTLD during the study period as assessed by the local site pathologist, with confirmation of the PTLD diagnosis by the Study Clinicopathological Review Board (SCPRB)

Measure: Incidence of Epstein-Barr Virus (EBV) Positive Post-Transplant Lymphoproliferative Disorders (PTLD)

Time: Receipt of transplanted organ(s) to confirmation of EBV-positive PTLD, up to year 4 post - enrollment

Description: Specified gain-of-function mutations in EBV LMP-1 (e.g., corresponding to EBV LMP-1 variants G212S or S366T) detected by polymerase chain reaction (PCR) method

Measure: Specified Gain-of-Function Mutations in EBV Latent Membrane Protein 1 (LMP-1)

Time: Receipt of transplanted organ(s) to confirmation of mutations in EBV LMP1 , up to year 4 post - enrollment

Description: Pathogenic changes in B cell clonotype development as assessed using high throughput sequencing (HTS)

Measure: Pathogenic Changes in B Cell Clonotype Development

Time: Receipt of transplanted organ(s) to confirmation of changes in B cell clonotype development, up to year 4 post - enrollment


HPO Nodes


Lymphoproliferative disorder
Genes 9
KRAS ZAP70 MYD88 NRAS IL2RG MYD88 CD70 MCM4 CD27